Endovascular treatment of chronic ilio-femoral vein obstruction with extension below the inguinal ligament in patients with post-thrombotic syndrome.

•Type of Research: Single-center, retrospective, non-randomized cohort study•Key Findings: Poor inflow and Villalta scale > 15 points at admissionwere predictive for in-stent occlusion over the follow-up. Proper inflow ensures the patency of the treated iliac axis.•Take home Message: The use of a dedicated venous stent across the inguinal ligament is feasible and safe, with acceptable primary and secondary patency rates and a low rate of complications in the early and medium term. BackgroundThis study aimed to evaluate postoperative outcomes of patients with chronic iliofemoral venous outflow obstruction and post-thrombotic syndrome (PTS) who underwent endovascular recanalization and stenting across the inguinal ligament.MethodsAll consecutive patients with chronic iliofemoral venous outflow obstruction and PTS were included in the analysis, from January 2018 and February 2022. Preoperative, intraoperative, and postoperative outcomes were assessed. Primary endpoints analyzed were major adverse events (MAEs) at 30 days and primary patency rate at 2 years of follow-up. Secondary endpoints assessed were secondary patency rate, target vessel revascularization (TVR), and clinical improvement evaluated with the venous clinical severity score (VCSS) classification, Villalta scale, and visual analog scale (VAS), respectively.ResultsA total of 63 patients (mean age: 48.1 ± 15.5 years; female: 61.9%) were evaluated. No intraoperative and 30-day postoperative complications were documented. The technical success rate was achieved at 100%. Overall, one in-stent occlusion and five in-stent restenosis were detected during follow-up. The primary patency rate was 93.7% (CI: 87.8% - 99.9%) and 92.1% (CI: 85.6% - 99%), at 1 and 2-year follow-up, respectively (Kaplan Meier analysis). Target vessel revascularization was conducted in two cases resulting in a secondary patency of 98.4% (CI: 95.4 % – 100%) at 2 years of follow-up. Stent fracture and/or migration were not observed during follow-up. A significant clinical improvement in the patient's quality of life was documented. The median improvement of VCSS and Villalta scores were 4 (IQR: 2 – 7; P=.001), and 3 (IQR: 1.5 – 5; P=.001) versus baseline, at the last follow-up. Overall, pain reduction of 17 mm on the VAS scale was documented at 2 years of follow-up. At multivariate analysis, presence of trabeculation into the FV and DFV (OR 1.89; CI 0.15 – 6.11; P= .043), and Villalta scale > 15 points at admission (OR 1.89; CI 0.15 – 6.11; P= .043) were predictive for in-stent occlusion during the follow-up.ConclusionsThe use of a dedicated venous stent across the inguinal ligament was safe and effective for the treatment of symptomatic iliofemoral venous disease with acceptable primary and secondary patency rates at 2 years of follow-up. This study aimed to evaluate postoperative outcomes of patients with chronic iliofemoral venous outflow obstruction and post-thrombotic syndrome (PTS) who underwent endovascular recanalization and stenting across the inguinal ligament. All consecutive patients with chronic iliofemoral venous outflow obstruction and PTS were included in the analysis, from January 2018 and February 2022. Preoperative, intraoperative, and postoperative outcomes were assessed. Primary endpoints analyzed were major adverse events (MAEs) at 30 days and primary patency rate at 2 years of follow-up. Secondary endpoints assessed were secondary patency rate, target vessel revascularization (TVR), and clinical improvement evaluated with the venous clinical severity score (VCSS) classification, Villalta scale, and visual analog scale (VAS), respectively. A total of 63 patients (mean age: 48.1 ± 15.5 years; female: 61.9%) were evaluated. No intraoperative and 30-day postoperative complications were documented. The technical success rate was achieved at 100%. Overall, one in-stent occlusion and five in-stent restenosis were detected during follow-up. The primary patency rate was 93.7% (CI: 87.8% - 99.9%) and 92.1% (CI: 85.6% - 99%), at 1 and 2-year follow-up, respectively (Kaplan Meier analysis). Target vessel revascularization was conducted in two cases resulting in a secondary patency of 98.4% (CI: 95.4 % – 100%) at 2 years of follow-up. Stent fracture and/or migration were not observed during follow-up. A significant clinical improvement in the patient's quality of life was documented. The median improvement of VCSS and Villalta scores were 4 (IQR: 2 – 7; P=.001), and 3 (IQR: 1.5 – 5; P=.001) versus baseline, at the last follow-up. Overall, pain reduction of 17 mm on the VAS scale was documented at 2 years of follow-up. At multivariate analysis, presence of trabeculation into the FV and DFV (OR 1.89; CI 0.15 – 6.11; P= .043), and Villalta scale > 15 points at admission (OR 1.89; CI 0.15 – 6.11; P= .043) were predictive for in-stent occlusion during the follow-up. The use of a dedicated venous stent across the inguinal ligament was safe and effective for the treatment of symptomatic iliofemoral venous disease with acceptable primary and secondary patency rates at 2 years of follow-up.